JP2024541013A5 - - Google Patents
Info
- Publication number
- JP2024541013A5 JP2024541013A5 JP2024524693A JP2024524693A JP2024541013A5 JP 2024541013 A5 JP2024541013 A5 JP 2024541013A5 JP 2024524693 A JP2024524693 A JP 2024524693A JP 2024524693 A JP2024524693 A JP 2024524693A JP 2024541013 A5 JP2024541013 A5 JP 2024541013A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- volume
- weight
- cyclodextrin
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382964 | 2021-10-25 | ||
| EP21382964.1 | 2021-10-25 | ||
| PCT/EP2022/079659 WO2023072872A1 (en) | 2021-10-25 | 2022-10-24 | Tadalafil oral suspension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541013A JP2024541013A (ja) | 2024-11-06 |
| JP2024541013A5 true JP2024541013A5 (enExample) | 2025-11-04 |
Family
ID=78528864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524693A Pending JP2024541013A (ja) | 2021-10-25 | 2022-10-24 | タダラフィル経口懸濁剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250241911A1 (enExample) |
| EP (1) | EP4422599B1 (enExample) |
| JP (1) | JP2024541013A (enExample) |
| CN (1) | CN118284408A (enExample) |
| AU (1) | AU2022374786A1 (enExample) |
| CA (1) | CA3235733A1 (enExample) |
| DK (1) | DK4422599T3 (enExample) |
| FI (1) | FI4422599T3 (enExample) |
| MX (1) | MX2024005048A (enExample) |
| WO (1) | WO2023072872A1 (enExample) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7018658B2 (en) | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| US20060147531A1 (en) | 2003-07-01 | 2006-07-06 | Mojca Segula | Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate |
| SI21637A (sl) | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
| KR20070021806A (ko) | 2005-08-19 | 2007-02-23 | (주)아모레퍼시픽 | α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법 |
| KR100745515B1 (ko) | 2006-04-10 | 2007-08-02 | 주식회사 대웅제약 | 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법 |
| KR20160021095A (ko) | 2013-06-21 | 2016-02-24 | 욱크하르트 리미티드 | 탐술로신 또는 이의 염의 약학 조성물 |
| CZ2015225A3 (cs) | 2015-03-30 | 2016-10-12 | Zentiva, K.S. | Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI |
| EP3498264B1 (en) * | 2016-08-12 | 2023-11-08 | Hanmi Pharm. Co., Ltd. | Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets |
| EP3576741A1 (en) | 2017-02-02 | 2019-12-11 | Dukebox SP. Z O.O. | A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate |
| EP3473245A1 (en) | 2017-10-20 | 2019-04-24 | Veru Inc. | Controlled release oral tamsulosin hydrochloride |
| WO2020039263A2 (en) | 2018-08-18 | 2020-02-27 | Ftf Pharma Private Limited | Pharmaceutical suspension for oral dosage |
-
2022
- 2022-10-24 US US18/703,099 patent/US20250241911A1/en active Pending
- 2022-10-24 MX MX2024005048A patent/MX2024005048A/es unknown
- 2022-10-24 DK DK22809383.7T patent/DK4422599T3/da active
- 2022-10-24 CN CN202280077312.5A patent/CN118284408A/zh active Pending
- 2022-10-24 CA CA3235733A patent/CA3235733A1/en active Pending
- 2022-10-24 AU AU2022374786A patent/AU2022374786A1/en active Pending
- 2022-10-24 EP EP22809383.7A patent/EP4422599B1/en active Active
- 2022-10-24 WO PCT/EP2022/079659 patent/WO2023072872A1/en not_active Ceased
- 2022-10-24 FI FIEP22809383.7T patent/FI4422599T3/fi active
- 2022-10-24 JP JP2024524693A patent/JP2024541013A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025142338A5 (enExample) | ||
| JP2019131596A5 (enExample) | ||
| JP2020007356A5 (enExample) | ||
| JP2023116489A5 (enExample) | ||
| CZ300154B6 (cs) | Zpusob výroby potahovaných granulí s maskovanou chutí a potahovaná granule vyrobitelná tímto zpusobem | |
| HRP20230210T1 (hr) | Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida | |
| JP2006527195A (ja) | トリプタンおよびｎｓａｉｄを含む組成物 | |
| BRPI0610634A2 (pt) | combinação para a terapia de hiperplasia benigna da próstata | |
| EP2068823A2 (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| JP2005528429A (ja) | 活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物 | |
| RU2007117499A (ru) | Фармацевтические композиции, маскирующие вкус | |
| JP2024541013A5 (enExample) | ||
| JP2019532112A5 (ja) | 結節性痒疹を治療するための抗掻痒剤 | |
| JPS63258809A (ja) | 医薬活性成分の放出性にすぐれ、かつ苦味を隠蔽した細粒剤 | |
| JP6940279B2 (ja) | 注腸剤 | |
| JP2003511403A (ja) | ミルタザピンの新しい配合物 | |
| JP2003512330A (ja) | シクレソニド含有水性医薬組成物 | |
| CN101703511B (zh) | 复方坦洛新和非那雄胺缓释胶囊及其制备方法 | |
| JP4956981B2 (ja) | オキシメタゾリン含有水性組成物 | |
| SG11202109710QA (en) | Capsid assembly modulator solid formulation | |
| RU2024110746A (ru) | Пероральная суспензия тадалафила | |
| CN101703510A (zh) | 一种坦洛新和非那雄胺复方缓释片及其制备方法 | |
| CN105106250B (zh) | 一种灵芝总三萜组合物及其制备方法 | |
| US10328076B2 (en) | Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof | |
| JP2024500875A (ja) | ナラトリプタンを含む口腔内崩壊フィルム製剤 |